APP and Alzheimer disease: Considering these findings and the well-established associations between KPI(+)APP expression levels, amyloid plaque deposition, and AD pathology progression33–35, it is tempting to speculate that controlling APP isoform switches by manipulating RBFOX family proteins could be a potential therapeutic strategy to hamper disease progression.